MYOCARDITIS -- No Matter How Hard CDC Tries To Trivialize The Reports They Keep Coming and Are More Serious
From Rare to More Than Occasionally Fatal
In February I reported on a dose-response relationship between the mRMA inoculant and Myo/pericarditis established in VAERS, the under reported CDC data base of adverse effects following a vaccination. I refined that initial report here and here.
Those three reports all addressed significant warnings about the dose relationship between the mRNA concoction and myocarditis in young people. In 2021 CDC also reported that the number of confirmed cases of what they call “myopericarditis” were substantially greater after second dose of the mRNA inoculant than they were after first dose. CDC reported that at the time of their analysis (August 2021) there were 1,339 cases of “myopericarditis”in VAERS (Vaccine Adverse Effects Reporting System) and that 742 (55%) of those cases were confirmed.
As of September 2, 2022 VAERS contained 52,106 reports of myo/pericarditis. How many of those has CDC confirmed or are they even working to confirm?
There are two things of note shown in the following graph from OpenVAERS.com. First, the dramatic difference in reported cases of myo/pericarditis in people between the ages of 12 and 23 remains. Second, there is a clear dose relationship shown over doses 1, 2, and 3 for those between the ages of 31 and 76.
CDC’s latest data confirms that dose response:
More on this table later.
The Inoculant is now related to death from myo/pericarditis
In the September 6, 2022 issue of Circulation Patone and her colleagues in the United Kingdom report 100 deaths from myo/pericarditits between 1 and 28 days following inoculation with either the AstraZeneca or Pfizer inoculants. Fifty-one of those deaths were attributed to the AstraZeneca inoculant, 49 to the Pfizer substance.
The 100 (28.98%) people who died were among 345 people age 13 years or older who were admitted to hospital with myo/pericarditis following inoculation with either the AstraZeneca or the Pfizer preparations.
It is important to note that the inoculations occurred some nine months ago between December 1, 2020 and December 15, 2021. According to OpenVAERS.com in 2021 there were 29,410 reports of inoculant related myo/pericarditis which translates to 2,450 reports/month. For the first eight months of 2022 there have been 22,999 reports of inoculant myo/pericarditis in OpenVAERS.com or 2,874 reports/month. There is no data available from OpenVAERS on how many inoculant related myo/pericarditis deaths occurred in either 2021 or 2022 but based on the findings by Patone et al. it is likely that the number of inoculant related myo/pericarditis deaths will be found to be significant.
One would hope that CDC would unleash its scientific curiosity following the report by Patone et al. and take a very close look at VAERS to determine how many inoculant related myo/pericarditis deaths have occurred in the US.
Unfortunately, based on CDC’s history, an investigation to determine if causality exists is not likely.
Myocarditis and pericarditis have rarely been reported. When reported, the cases have especially been in adolescents and young adult males within several days after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna).
More often after the second dose
Usually within a week of vaccination
Most patients with myocarditis or pericarditis who received care responded well to medicine and rest and felt better quickly.
Patients can usually return to their normal daily activities after their symptoms improve.
Those who have been diagnosed with myocarditis should consult with their cardiologist (heart doctor) about return to exercise or sports.
The above text is from a July 14, 2022 update of CDC’s myo/pericarditis guidance. Asserting that inoculant related myo/pericarditis is “rarely” reported and that “most patients … responded well to medicine and rest and felt better quickly”, is small solace to the loved ones of those who died as a consequence of inoculant induced myo/pericarditis.
Even the agency’s latest presentation on the relationship between the inoculants and myo/pericarditis appears to have been made intentionally obtuse. While the centuries long accepted method of data presentation is to present variables on the y axis and sequence on the x axis in increasing order e.g. 1, 2, 3 … CDC has reversed the data presentation and is showing the data following the second dose of the Pfizer inoculant first and the first dose second which to the casual reader makes it appear that there is a decrease in frequency of myo/pericarditis with dose when in fact there is a clear increase.
On a final note, Dr. Kirk Milhoan a practicing, board certified, pediatric cardiologist stated during a lecture at the Gateway to Freedom Conference in Collinsville, Ill on August 26, 2022:
“We’re seeing something that we haven’t seen before,” he said on Aug. 26 at the Gateway to Freedom Conference in Collinsville, Illinois. “We haven’t seen a vaccine cause this level of myocarditis. It’s not one here or one there. It is a large number of people getting myocarditis from this vaccine.”
Dr. Milhoan concluded:
“The question is, why would we be putting children at risk if their risk from COVID is very low?”
Why indeed, Dr. Walensky?
Union, KY
16 September 2022